FSHD
10
3
3
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 10 trials
100.0%
+13.5% vs benchmark
10%
1 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (10)
Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)
Phase 2 Study Evaluating Apitegromab for the Treatment of FSHD
BetterLife FSHD: A Patient-driven Health and Research Platform
A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD
Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD)
Phase 2 Open-label Extension Study of AOC 1020 in Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)
Testing a Tailored Home Exercise Program to Reduce Pain and Fatigue in Patients with FSHD.
Pompe & Pain - Study to Assess Nociceptive Pain in Adult Patients With Pompe Disease
New Biomarkers in Facioscapulohumeral Muscular Dystrophy, Multispectral Optoacoustic Tomography.
Schulze Muscular Dystrophy Ability Clinical Study